» Articles » PMID: 36131114

Alteration of Rhesus Macaque Serum N-glycome During Infection with the Human Parasitic Filarial Nematode Brugia Malayi

Abstract

Serum N-glycan profiling studies during the past decades have shown robust associations between N-glycan changes and various biological conditions, including infections, in humans. Similar studies are scarcer for other mammals, despite the tremendous potential of serum N-glycans as biomarkers for infectious diseases in animal models of human disease and in the veterinary context. To expand the knowledge of serum N-glycan profiles in important mammalian model systems, in this study, we combined MALDI-TOF-MS analysis and HILIC-UPLC profiling of released N-glycans together with glycosidase treatments to characterize the glycan structures present in rhesus macaque serum. We used this baseline to monitor changes in serum N-glycans during infection with Brugia malayi, a parasitic nematode of humans responsible for lymphatic filariasis, in a longitudinal cohort of infected rhesus macaques. Alterations of the HILIC-UPLC profile, notably of abundant structures, became evident as early as 5 weeks post-infection. Given its prominent role in the immune response, contribution of immunoglobulin G to serum N-glycans was investigated. Finally, comparison with similar N-glycan profiling performed during infection with the dog heartworm Dirofilaria immitis suggests that many changes observed in rhesus macaque serum N-glycans are specific for lymphatic filariasis.

References
1.
Khatri V, Chauhan N, Vishnoi K, von Gegerfelt A, Gittens C, Kalyanasundaram R . Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates. Int J Parasitol. 2018; 48(9-10):773-783. PMC: 6054809. DOI: 10.1016/j.ijpara.2018.04.002. View

2.
Kirwan A, Utratna M, ODwyer M, Joshi L, Kilcoyne M . Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. Biomed Res Int. 2015; 2015:490531. PMC: 4609776. DOI: 10.1155/2015/490531. View

3.
Wittenbecher C, Stambuk T, Kuxhaus O, Rudman N, Vuckovic F, Stambuk J . Plasma -Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study. Diabetes Care. 2020; 43(3):661-668. DOI: 10.2337/dc19-1507. View

4.
Dekkers G, Treffers L, Plomp R, Bentlage A, de Boer M, Koeleman C . Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. Front Immunol. 2017; 8:877. PMC: 5539844. DOI: 10.3389/fimmu.2017.00877. View

5.
Kiyoshi M, Caaveiro J, Tada M, Tamura H, Tanaka T, Terao Y . Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column. Sci Rep. 2018; 8(1):3955. PMC: 5834517. DOI: 10.1038/s41598-018-22199-8. View